Recent News
Read ArticleMore than half of U.S. adults use dietary supplements, yet only a quarter use supplements recommended by a healthcare professional, and current law lets supplements reach the market with no premarket safety evaluation, unlike drugs or food additives.
Gout in Minority Populations
Gout is the most common inflammatory arthritis, but its burden is not shared equally across populations. Recent research has revealed substantial racial and ethnic disparities in both who develops gout and the care patients receive. These differences reflect not only genetic susceptibility but also the substantial influence of social determinants of health, healthcare access, and environmental exposures.
Read Article
Learn more about the fundamentals of CAR T-cell therapy and its investigational use in autoimmune disease.
Sponsored by Bristol Myers Squibb. https://t.co/VvTOYY3tvz
#CARTCellTherapy https://t.co/3LvQu24dVQ
Dr. John Cush @RheumNow ( View Tweet)
Glucocorticoid use in 1st yr of 574 newly DX RA cases-- 75% recv GC in 1st yr; 313 (55%) Rx at 1st visit. (m GC dose =9.3 mg/day. 1/2 (47%) recv IA GC injx. 20% had 1st yr infx. Risk of infx was NS (RR 1.13; 0.77 to 1.67) for 0-10 mg/d vs no GC https://t.co/s9YaGZsUjr https://t.co/ESHvVK1Egx
Dr. John Cush @RheumNow ( View Tweet)
Metanalysis of 31 studies (14,548 pts) looked at infection in idiopathic inflamm myopathy (IIMs). Infection prevalence was 24%, primarily Respiratory tract. PJP, aspergillosis, H zoster most prevalent pathogens. Risk factors: older age, male, DM, HTN,MDA5+ (OR 3.41), rapidly https://t.co/Go51MUOQlG
Dr. John Cush @RheumNow ( View Tweet)
Congratulations to Dr. Chandra Mohan and Univ. of Houston for receiving a $4 million NIH grant for a 10-year longitudinal study to identify the earliest biological triggers of autoimmune disease https://t.co/6kMcv9PD5r https://t.co/CsY8QAxrXR
Dr. John Cush @RheumNow ( View Tweet)
Hip Replacement Advances
Hip replacement surgery has been a major advance in the management of patients with hip damage and diminishing quality of life. While this review provides new information regarding a new type of hardware (end of article), lets begin with a general overview.
Read Article
Why Do Gout Flares Start at Night?
The striking propensity for gout flares to initiate at night has been recognised for centuries. In 1683, Thomas Sydenham famously observed that the typical patient "goes to bed and sleeps in good health" only to be awakened around 2:00 AM by excruciating pain.
Read Article
Retrospective study 1420 newly Dx non-tuberculous mycobacterial (NTM) infx (2012-2024) - 66 (4.6%) Dx w/ RA (55 after RA dx). Having RA + NTM incr risk of Resp. death (HR 4.3) w/ lower 5yr survival (75% vs 93%) partly explained by ILD and sytemic inflamm. https://t.co/6sdR7XwwD7
Dr. John Cush @RheumNow ( View Tweet)
In 2010 Colchicine fell under patent protection and price increased 16 fold, & out-of-pocket price increased 4.4-fold, colchicine use decreased 27%, while allopurinol, steroid & gout visits (ER, Rheum) increased. https://t.co/xyOxsnoM5z https://t.co/yoXehV0mPa
Dr. John Cush @RheumNow ( View Tweet)
CAR-T Therapy: EULAR 2026 Conference Recap
https://t.co/XALrMFReOe https://t.co/TK0ot8MZb6
Dr. John Cush @RheumNow ( View Tweet)
Do we need Better Strategies to Prevent Osteoporotic Fractures?
In a recent JAMA Viewpoints article, Dr. Susan Ott addresses several controversies in preventing osteoporosis (OP) related fractures.
https://t.co/YpmyZGCsjz https://t.co/NUkJVcxBjc
Dr. John Cush @RheumNow ( View Tweet)
Gout Cavalcade (7.10.2026)
Dr. Jack Cush reviews the news, journal articles and regulatory decisions from the past week. July is Gout: More than Flares month.
https://t.co/I1zWdx9fzU https://t.co/EYQ3D9Z42t
Dr. John Cush @RheumNow ( View Tweet)
Guidelines to Spot Cancer in High Risk Dermatomyositis
MedPage Today
International guidelines can help identify dermatomyositis patients with a particularly high risk for cancer, according to a retrospective single-center U.S. study.
Read Article
While not a validated Dx tool for gout, AI retinal scanning of digital fundus photography was tested on 107730 pts & showed high ROC - f NIDDM 0.833, Gout 0.832, OP 0.787, HTN 0.740, hyperlipidemia 0.736 & thyroid Dz 0.699 https://t.co/1yrlR04z4g https://t.co/c04YtVVERY
Dr. John Cush @RheumNow ( View Tweet)
RHEUMATOLOGIST SURVEY ON GOUT - In what percentage of your new Gout patients, do you do arthrocentesis and crystal ID? Answer here: https://t.co/jpebQev4VU
Dr. John Cush @RheumNow ( View Tweet)
RZV (Shingrix) response in 76 immunosuppressed SSc & 304 controls (CG) recv two RZV doses. High seroconversion seen in SSc but signif lower than CG (92.6% vs 99.7%, P 0.001), w/ lower concentration but comparable CMI, lower AE (74% vs 86%) https://t.co/ALlnVEZIAt https://t.co/kYYy2JIo2J
Dr. John Cush @RheumNow ( View Tweet)
20 yr. Tx trends in 6583 #SSc pts. 2005 to 2025 endothelin receptor antagonists & prostanoids/prostacyclins from 3% to 28%. CCB & PDE-5 inh stable. CTX shifted to mycophenolate, RTX, & nintedanib. Steriods decr from 50% to 18% https://t.co/nrm1Ov285f https://t.co/ftLn3bGH72
Dr. John Cush @RheumNow ( View Tweet)
Registration is now open!
Join Dr. Jack Cush as he moderates an expert discussion with Dr. Nicola Dalbeth, Dr. John Fitzgerald, and Dr. Sarah Tedeschi on the evolving role of imaging in gout.
Topics include:
🔹 Ultrasound
🔹 Dual-energy CT (DECT)
🔹 Crystal identification
🔹 https://t.co/iOOAAAEneX
Dr. John Cush @RheumNow ( View Tweet)
True or False: Extreme weight loss methods such as bariatric surgery and ketogenic diets may trigger gouty attacks, unlike GLP-1 agonist-induced weight loss.
Test your RheumIQ in this week's quiz at https://t.co/8BuwihOvfE.
Dr. John Cush @RheumNow ( View Tweet)
Video
From the Blog
At first, it seemed similar to many other such sessions – a circle of folding chairs, a group of colleagues whose visages exuded understanding and acceptance – but this was special. I started the meeting…. “Hi, my name is Artie.”
Read Post
Podcasts
What Lies Beneath - Uric Acid Deposition & Imaging
Gout QD clinics - lessons from the Clinic QD307-QD311
Gout Cavalcade (7.10.2026)
Gout Journal Club
Therapeutic Updates
Fundamentals of CAR T Cell Therapy and Its Investigational Use in Autoimmune Diseases
Sponsored By Bristol Myers Squibb
Learn more about the fundamentals of CAR T-cell therapy and its investigational use in autoimmune disease
Read Post
Watch our 'Systemic Burden of Gout' series as part of this month's Gout More than Flares campaign. Now available: 3 New Things It Pays to Know About Gout Pathobiology, Outcomes of Tophaceous Gout & Subclinical Inflammation in Intercritical Gout.
Read Post
Poster Hall
Sponsored by AbbVie Medical Affairs + Health Impact
Real-World Joint Outcomes With an IL-23i vs TNFi or IL-17i in PsA
Daily Gem
Less than 10% of gout patients have crystal-proven gout.
--